1. Home
  2. KOSS vs CGTX Comparison

KOSS vs CGTX Comparison

Compare KOSS & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Koss Corporation

KOSS

Koss Corporation

HOLD

Current Price

$4.34

Market Cap

43.6M

ML Signal

HOLD

Logo Cognition Therapeutics Inc.

CGTX

Cognition Therapeutics Inc.

HOLD

Current Price

$1.43

Market Cap

132.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KOSS
CGTX
Founded
1953
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Consumer Electronics/Appliances
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
43.6M
132.4M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
KOSS
CGTX
Price
$4.34
$1.43
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$2.88
AVG Volume (30 Days)
33.9K
957.8K
Earning Date
01-29-2026
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$13,493,080.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
11.58
N/A
52 Week Low
$4.00
$0.22
52 Week High
$8.59
$3.83

Technical Indicators

Market Signals
Indicator
KOSS
CGTX
Relative Strength Index (RSI) 39.27 42.87
Support Level $4.35 $1.37
Resistance Level $4.80 $1.62
Average True Range (ATR) 0.19 0.12
MACD -0.01 -0.02
Stochastic Oscillator 15.83 15.36

Price Performance

Historical Comparison
KOSS
CGTX

About KOSS Koss Corporation

Koss Corp is engaged in the design, manufacture, and sale of stereo headphones and related accessory products. It operates in the audio/video industry segment of the home entertainment industry. The company markets a line of headphones, wireless Bluetooth headphones, wireless Bluetooth speakers, computer headsets, telecommunications headsets, and active noise-canceling headphones. The majority of the firm's revenue is derived from sales of stereo headphones. The Company also sells products to distributors for resale to school systems, and directly to other manufacturers for inclusion with their own products.

About CGTX Cognition Therapeutics Inc.

Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.

Share on Social Networks: